Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2009

Open Access 01-12-2009 | Research article

A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice

Authors: Liyun Zheng, Fuyan Wang, Zhongdong Yang, Jianjun Chen, Haiyan Chang, Ze Chen

Published in: BMC Infectious Diseases | Issue 1/2009

Login to get access

Abstract

Background

Developing vaccines for the prevention of human infection by H5N1 influenza viruses is an urgent task. DNA vaccines are a novel alternative to conventional vaccines and should contribute to the prophylaxis of emerging H5N1 virus. In this study, we assessed whether a single immunization with plasmid DNA expressing H5N1 hemagglutinin (HA) could provide early protection against lethal challenge in a mouse model.

Methods

Mice were immunized once with HA DNA at 3, 5, 7 days before a lethal challenge. The survival rate, virus titer in the lungs and change of body weight were assayed to evaluate the protective abilities of the vaccine. To test the humoral immune response induced by HA DNA, serum samples were collected through the eye canthus of mice on various days after immunization and examined for specific antibodies by ELISA and an HI assay. Splenocytes were isolated after the immunization to determine the antigen-specific T-cell response by the ELISPOT assay.

Results

Challenge experiments revealed that a single immunization of H5N1 virus HA DNA is effective in early protection against lethal homologous virus. Immunological analysis showed that an antigen-specific antibody and T-cell response could be elicited in mice shortly after the immunization. The protective abilities were correlated with the amount of injected DNA and the length of time after vaccination.

Conclusion

A single immunization of 100 μg H5 HA DNA vaccine combined with electroporation was able to provide early protection in mice against homologous virus infection.
Appendix
Available only for authorised users
Literature
1.
Lipatov AS, Govorkova EA, Webby RJ, Ozaki H, Peiris M, Guan Y, Poon L, Webster RG: Influenza: emergence and control. J Virol. 2004, 78 (17): 8951-8959. 10.1128/JVI.78.17.8951-8959.2004.CrossRefPubMedPubMedCentral
2.
Chen H, Deng G, Li Z, Tian G, Li Y, Jiao P, Zhang L, Liu Z, Webster RG, Yu K: The evolution of H5N1 influenza viruses in ducks in southern China. Proc Natl Acad Sci USA. 2004, 101 (28): 10452-10457. 10.1073/pnas.0403212101.CrossRefPubMedPubMedCentral
3.
Hinshaw VS, Webster RG, Turner B: The perpetuation of orthomyxoviruses and paramyxoviruses in Canadian waterfowl. Can J Microbiol. 1980, 26 (5): 622-629.CrossRefPubMed
4.
Sharp NJ, Sullivan M, Harvey CE, Webb T: Treatment of canine nasal aspergillosis with enilconazole. J Vet Intern Med. 1993, 7 (1): 40-43.CrossRefPubMed
5.
Horimoto T, Kawaoka Y: Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol. 2005, 3 (8): 591-600. 10.1038/nrmicro1208.CrossRefPubMed
6.
Xu X, Subbarao , Cox NJ, Guo Y: Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology. 1999, 261 (1): 15-19. 10.1006/viro.1999.9820.CrossRefPubMed
7.
Kodihalli S, Haynes JR, Robinson HL, Webster RG: Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin. J Virol. 1997, 71 (5): 3391-3396.PubMedPubMedCentral
8.
Shortridge KF: Pandemic influenza: a zoonosis?. Semin Respir Infect. 1992, 7 (1): 11-25.PubMed
9.
Tran TH, Nguyen TL, Nguyen TD, Luong TS, Pham PM, Nguyen VC, Pham TS, Vo CD, Le TQ, Ngo TT, et al: Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med. 2004, 350 (12): 1179-1188. 10.1056/NEJMoa040419.CrossRefPubMed
10.
Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, Uiprasertkul M, Boonnak K, Pittayawonganon C, Cox NJ, et al: Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med. 2005, 352 (4): 333-340. 10.1056/NEJMoa044021.CrossRefPubMed
11.
Normile D: Avian influenza. Human transmission but no pandemic in Indonesia. Science. 2006, 312 (5782): 1855-10.1126/science.312.5782.1864.CrossRef
12.
Lin YP, Shaw M, Gregory V, Cameron K, Lim W, Klimov A, Subbarao K, Guan Y, Krauss S, Shortridge K, et al: Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad Sci USA. 2000, 97 (17): 9654-9658. 10.1073/pnas.160270697.CrossRefPubMedPubMedCentral
13.
Guan Y, Shortridge KF, Krauss S, Webster RG: Molecular characterization of H9N2 influenza viruses: were they the donors of the "internal" genes of H5N1 viruses in Hong Kong?. Proc Natl Acad Sci USA. 1999, 96 (16): 9363-9367. 10.1073/pnas.96.16.9363.CrossRefPubMedPubMedCentral
14.
Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, Katz JM: A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol. 1999, 73 (7): 5903-5911.PubMedPubMedCentral
15.
Middleton D, Bingham J, Selleck P, Lowther S, Gleeson L, Lehrbach P, Robinson S, Rodenberg J, Kumar M, Andrew M: Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks. Virology. 2007, 359 (1): 66-71. 10.1016/j.virol.2006.08.046.CrossRefPubMed
16.
Chen H, Smith GJ, Li KS, Wang J, Fan XH, Rayner JM, Vijaykrishna D, Zhang JX, Zhang LJ, Guo CT, et al: Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci USA. 2006, 103 (8): 2845-2850. 10.1073/pnas.0511120103.CrossRefPubMedPubMedCentral
17.
Kodihalli S, Kobasa DL, Webster RG: Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine. 2000, 18 (23): 2592-2599. 10.1016/S0264-410X(99)00485-5.CrossRefPubMed
18.
Kodihalli S, Goto H, Kobasa DL, Krauss S, Kawaoka Y, Webster RG: DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J Virol. 1999, 73 (3): 2094-2098.PubMedPubMedCentral
19.
Ljungberg K, Wahren B, Almqvist J, Hinkula J, Linde A, Winberg G: Effective construction of DNA vaccines against variable influenza genes by homologous recombination. Virology. 2000, 268 (2): 244-250. 10.1006/viro.2000.0199.CrossRefPubMed
20.
Ljungberg K, Kolmskog C, Wahren B, van Amerongen G, Baars M, Osterhaus A, Linde A, Rimmelzwaan G: DNA vaccination of ferrets with chimeric influenza A virus hemagglutinin (H3) genes. Vaccine. 2002, 20 (16): 2045-2052. 10.1016/S0264-410X(02)00049-X.CrossRefPubMed
21.
Lee CW, Senne DA, Suarez DL: Development of hemagglutinin subtype-specific reference antisera by DNA vaccination of chickens. Avian Dis. 2003, 47 (3 Suppl): 1051-1056. 10.1637/0005-2086-47.s3.1051.CrossRefPubMed
22.
Cherbonnel M, Rousset J, Jestin V: Strategies to improve protection against low-pathogenicity H7 avian influenza virus infection using DNA vaccines. Avian Dis. 2003, 47 (3 Suppl): 1181-1186. 10.1637/0005-2086-47.s3.1181.CrossRefPubMed
23.
Chen Z, Sahashi Y, Matsuo K, Asanuma H, Takahashi H, Iwasaki T, Suzuki Y, Aizawa C, Kurata T, Tamura S: Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza. Vaccine. 1998, 16 (16): 1544-1549. 10.1016/S0264-410X(98)00043-7.CrossRefPubMed
24.
Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Matsuo K, Kurata T, Tamura S: Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine. 2000, 18 (28): 3214-3222. 10.1016/S0264-410X(00)00149-3.CrossRefPubMed
25.
Kadowaki S, Chen Z, Asanuma H, Aizawa C, Kurata T, Tamura S: Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation. Vaccine. 2000, 18 (25): 2779-2788. 10.1016/S0264-410X(00)00087-6.CrossRefPubMed
26.
Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Sata T, Kurata T, Tamura S: Protection against influenza B virus infection by immunization with DNA vaccines. Vaccine. 2001, 19 (11–12): 1446-1455. 10.1016/S0264-410X(00)00351-0.CrossRefPubMed
27.
Chen J, Fang F, Li X, Chang H, Chen Z: Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation. Vaccine. 2005, 23 (34): 4322-4328. 10.1016/j.vaccine.2005.03.035.CrossRefPubMed
28.
Qiu M, Fang F, Chen Y, Wang H, Chen Q, Chang H, Wang F, Wang H, Zhang R, Chen Z: Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice. Biochem Biophys Res Commun. 2006, 343 (4): 1124-1131. 10.1016/j.bbrc.2006.03.088.CrossRefPubMed
29.
Reed LJ, Muench H: A simple method of estimating fifty per cent endpoints. AmJHyg. 1938, 27: 493-497.
30.
Niwa H, Yamamura K, Miyazaki J: Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991, 108 (2): 193-199. 10.1016/0378-1119(91)90434-D.CrossRefPubMed
31.
Aihara H, Miyazaki J: Gene transfer into muscle by electroporation in vivo. Nat Biotechnol. 1998, 16 (9): 867-870. 10.1038/nbt0998-867.CrossRefPubMed
32.
Tamura SI, Asanuma H, Ito Y, Hirabayashi Y, Suzuki Y, Nagamine T, Aizawa C, Kurata T, Oya A: Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol. 1992, 22 (2): 477-481. 10.1002/eji.1830220228.CrossRefPubMed
33.
Phelan MA, Mayner RE, Bucher DJ, Ennis FA: Purification of influenza virus glycoproteins for the preparation and standardization of immunological potency testing reagents. J Biol Stand. 1980, 8 (3): 233-242. 10.1016/S0092-1157(80)80039-4.CrossRefPubMed
34.
Webster RG, Kawaoka Y, Taylor J, Weinberg R, Paoletti E: Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine. 1991, 9 (5): 303-308. 10.1016/0264-410X(91)90055-B.CrossRefPubMed
35.
Laddy DJ, Yan J, Corbitt N, Kobasa D, Kobinger GP, Weiner DB: Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine. 2007, 25 (16): 2984-2989. 10.1016/j.vaccine.2007.01.063.CrossRefPubMedPubMedCentral
36.
Subbarao K, Chen H, Swayne D, Mingay L, Fodor E, Brownlee G, Xu X, Lu X, Katz J, Cox N, et al: Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology. 2003, 305 (1): 192-200. 10.1006/viro.2002.1742.CrossRefPubMed
37.
Katz JM: The impact of avian influenza viruses on public health. Avian Dis. 2003, 47 (3 Suppl): 914-920. 10.1637/0005-2086-47.s3.914.CrossRefPubMed
38.
Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL: DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA. 1993, 90 (24): 11478-11482. 10.1073/pnas.90.24.11478.CrossRefPubMedPubMedCentral
39.
Ulmer JB, Deck RR, DeWitt CM, Friedman A, Donnelly JJ, Liu MA: Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vaccine. 1994, 12 (16): 1541-1544. 10.1016/0264-410X(94)90081-7.CrossRefPubMed
40.
Johnson PA, Conway MA, Daly J, Nicolson C, Robertson J, Mills KH: Plasmid DNA encoding influenza virus haemagglutinin induces Th1 cells and protection against respiratory infection despite its limited ability to generate antibody responses. J Gen Virol. 2000, 81: 1737-1745.CrossRefPubMed
41.
Deck RR, DeWitt CM, Donnelly JJ, Liu MA, Ulmer JB: Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine. Vaccine. 1997, 15 (1): 71-78. 10.1016/S0264-410X(96)00101-6.CrossRefPubMed
42.
Tsang C, Babiuk S, van Drunen Littel-van den Hurk S, Babiuk LA, Griebel P: A single DNA immunization in combination with electroporation prolongs the primary immune response and maintains immune memory for six months. Vaccine. 2007, 25 (30): 5485-5494. 10.1016/j.vaccine.2007.03.009.CrossRefPubMed
43.
Kuklin N, Daheshia M, Karem K, Manickan E, Rouse BT: Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J Virol. 1997, 71 (4): 3138-3145.PubMedPubMedCentral
44.
Riberdy JM, Flynn KJ, Stech J, Webster RG, Altman JD, Doherty PC: Protection against a lethal avian influenza A virus in a mammalian system. J Virol. 1999, 73 (2): 1453-1459.PubMedPubMedCentral
45.
Pertmer TM, Roberts TR, Haynes JR: Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol. 1996, 70 (9): 6119-6125.PubMedPubMedCentral
46.
Feltquate DM, Heaney S, Webster RG, Robinson HL: Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol. 1997, 158 (5): 2278-2284.PubMed
47.
Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M: Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006, 354 (13): 1343-1351. 10.1056/NEJMoa055778.CrossRefPubMed
48.
Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, Hons E, Devaster JM, Leroux-Roels G: Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007, 370 (9587): 580-589. 10.1016/S0140-6736(07)61297-5.CrossRefPubMed
49.
Nolan TM, Richmond PC, Skeljo MV, Pearce G, Hartel G, Formica NT, Hoschler K, Bennet J, Ryan D, Papanaoum K, et al: Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine. 2008, 26 (33): 4160-4167. 10.1016/j.vaccine.2008.05.077.CrossRefPubMed
50.
Nolan T, Richmond PC, Formica NT, Hoschler K, Skeljo MV, Stoney T, McVernon J, Hartel G, Sawlwin DC, Bennet J, et al: Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine. 2008, 26 (50): 6383-6391. 10.1016/j.vaccine.2008.08.046.CrossRefPubMed
Metadata
Title
A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice
Authors
Liyun Zheng
Fuyan Wang
Zhongdong Yang
Jianjun Chen
Haiyan Chang
Ze Chen
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2009
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-9-17

Other articles of this Issue 1/2009

BMC Infectious Diseases 1/2009 Go to the issue

Research article

Initial psychological responses to Influenza A, H1N1 ("Swine flu")

Research article

Improving survey methods in sero-epidemiological studies of injecting drug users: a case example of two cross sectional surveys in Serbia and Montenegro

Research article

Different inflammatory responses are associated with Ureaplasma parvum-induced UTI and urolith formation

Research article

Comparison of oral and vaginal metronidazole for treatment of bacterial vaginosis in pregnancy: impact on fastidious bacteria

Research article

The epidemiology of pertussis in Germany: past and present

Research article

Outbreaks of Streptococcus pneumoniaecarriage in day care cohorts in Finland – implications for elimination of transmission
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits